Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen
Treatment for Hiv Aids Drug Susceptible Tuberculosis
Typical Dosage: Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
Effectiveness
90%
Safety Score
60%
Clinical Trials
5,000
Participants
5M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Weight-based daily or thrice-weekly dosing for Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
Time to Effect
1-2 weeks for clinical improvement, 2-4 weeks for sputum conversion
Treatment Duration
6 months (2 months intensive, 4 months continuation)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
1(Treat 1 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
20(Treat 20 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$680
Monitoring:$2,300
Side Effect Mgmt:$350
Total Annual:$3,330
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$8,000/QALY
QALYs Gained
12
Outcome-Based Costs
Cost per Responder
$3,700
Cost per Remission
$3,918
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) followed by Isoniazid, Rifampicin (HR) Regimen Outcomes
for Hiv Aids Drug Susceptible Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Hepatotoxicity (elevated LFTs, hepatitis)
+8%
Peripheral neuropathy
+5%
Gastrointestinal upset (nausea, vomiting, abdominal pain)
+15%
Orange/red discoloration of urine/tears/sweat
+99%
Arthralgia
+15%
Optic neuritis
+3%
Rash
+3%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov